CVRx (NASDAQ:CVRX) Issues Quarterly Earnings Results

CVRx (NASDAQ:CVRX) issued its earnings results on Tuesday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06), Zacks reports. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%.

CVRx Price Performance

CVRx stock traded up $0.79 during trading on Tuesday, reaching $16.25. The company had a trading volume of 268,521 shares, compared to its average volume of 262,124. CVRx has a 1-year low of $6.40 and a 1-year high of $25.04. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. The firm’s 50-day simple moving average is $14.69 and its 200 day simple moving average is $11.66. The firm has a market capitalization of $394.23 million, a PE ratio of -6.02 and a beta of 1.29.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CVRX shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $14.00 price target on shares of CVRx in a research report on Wednesday, October 23rd. Canaccord Genuity Group lifted their price target on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Lake Street Capital upped their price objective on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Craig Hallum lifted their target price on shares of CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, January 17th. Finally, Piper Sandler reissued an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of CVRx in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, CVRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.